Teachers Retirement System of The State of Kentucky Makes New $694,000 Investment in MBX Biosciences, Inc. (NYSE:MBX)

Teachers Retirement System of The State of Kentucky bought a new position in MBX Biosciences, Inc. (NYSE:MBX - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 26,708 shares of the company's stock, valued at approximately $694,000. Teachers Retirement System of The State of Kentucky owned about 0.08% of MBX Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of MBX Biosciences in the 3rd quarter valued at $278,000. Point72 Asset Management L.P. purchased a new position in shares of MBX Biosciences in the 3rd quarter worth $405,000. Barclays PLC acquired a new position in MBX Biosciences in the third quarter valued at $426,000. Geode Capital Management LLC acquired a new position in MBX Biosciences in the third quarter valued at $579,000. Finally, Point72 DIFC Ltd purchased a new stake in MBX Biosciences during the third quarter valued at about $624,000.

MBX Biosciences Stock Performance

Shares of NYSE:MBX traded up $0.78 during mid-day trading on Thursday, hitting $20.27. 351,473 shares of the company traded hands, compared to its average volume of 143,910. The stock's 50 day moving average price is $21.18. MBX Biosciences, Inc. has a 52-week low of $15.31 and a 52-week high of $27.50.

MBX Biosciences (NYSE:MBX - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($2.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.72) by ($0.06). Analysts predict that MBX Biosciences, Inc. will post -13.21 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on MBX. Stifel Nicolaus began coverage on MBX Biosciences in a research note on Tuesday, October 8th. They issued a "buy" rating and a $40.00 price objective on the stock. JPMorgan Chase & Co. assumed coverage on shares of MBX Biosciences in a report on Tuesday, October 8th. They issued an "overweight" rating and a $30.00 price target on the stock. Guggenheim assumed coverage on shares of MBX Biosciences in a research note on Tuesday, October 8th. They set a "buy" rating and a $44.00 price objective for the company. Finally, Jefferies Financial Group began coverage on shares of MBX Biosciences in a research note on Tuesday, October 8th. They issued a "buy" rating and a $35.00 target price on the stock.

MBX Biosciences Company Profile

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.